A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in People With Celiac Disease

Study Purpose

This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 70 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Previous diagnosis of celiac disease based on histology and positive celiac serology.
  • - HLA-DQ2.5 genotype.
  • - Gluten-free diet for at least 12 months.
  • - Negative or weak positive for transglutaminase IgA and negative or weak positive for DGP-IgA/IgG during screening.

Exclusion Criteria:

  • - Refractory celiac disease.
  • - HLA-DQ8 genotype.
  • - Previous oral gluten challenge within 12 months.
  • - Selective IgA deficiency.
  • - Diagnosis of Type-1 diabetes.
  • - Active gastrointestinal diseases.
- History of dermatitis herpetiformis

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05574010
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1/Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Alison Long, MD, PhD
Principal Investigator Affiliation Anokion SA
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Celiac Disease
Additional Details

The study is a 2-part, multicenter Phase 1b/2 study of KAN-101 in participants with Celiac Disease (CeD) on a gluten free diet (GFD). The 2 parts include:

  • - Part A - Open-label, multiple ascending dose.
  • - Part B - Double-blind, placebo-controlled, parallel design.
Part A is a Phase 1b, open-label, multiple ascending dose (MAD) study design to assess the safety, tolerability, and pharmacokinetics (PK) of KAN-101 in adult participants (18 to 70 years inclusive) with histology-confirmed CeD. Up to 18 participants who meet study inclusion/exclusion criteria will receive 1 of 3 dose levels of KAN-101. The overall study duration will be about 56 days, including up to 28 days of screening, 7 days of treatment and 21 days of follow up. There will be a gluten challenge test (GC) on Day 15. Part B is a Phase 2, double-blind, placebo-controlled, parallel design study to characterize the biomarker response following GC, safety, tolerability, and PK of KAN-101 in adult participants with histology-confirmed CeD. 120 participants (30 participants per dose group) will be randomized 1:1:1:1 and stratified by participation in a biopsy substudy to 4 treatment groups: placebo and 3 treatment groups with KAN-101 doses to be determined based on information obtained from Part A.

Arms & Interventions

Arms

Experimental: Cohort 1 in Part A

All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 1

Experimental: Cohort 2 in Part A

All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 2

Experimental: Cohort 3 in Part A

All eligible Part A participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 3

Placebo Comparator: Group 1 in Part B

All eligible Part B participants will receive 3 intravenous (IV) infusions of placebo

Experimental: Group 2 in Part B

All eligible Part B participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 4

Experimental: Group 3 in Part B

All eligible Part B participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 5

Experimental: Group 4 in Part B

All eligible Part B participants will receive 3 intravenous (IV) infusions of KAN-101 Dose 6

Interventions

Drug: - Cohort 1 in Part A

Dose 1 KAN-101 Intravenous (IV) infusion

Drug: - Cohort 2 in Part A

Dose 2 KAN-101 Intravenous (IV) infusion

Drug: - Cohort 3 in Part A

Dose 3 KAN-101 Intravenous (IV) infusion

Other: - Placebo: Group 1 in Part B

Placebo Intravenous (IV) infusion

Drug: - Group 2 in Part B

Dose 4 KAN-101 Intravenous (IV) infusion

Drug: - Group 3 in Part B

Dose 5 KAN-101 Intravenous (IV) infusion

Drug: - Group 4 in Part B

Dose 6 KAN-101 Intravenous (IV) infusion

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota

Status

Recruiting

Address

Prism Research LLC dba Nucleus Network

Saint Paul, Minnesota, 55114

Site Contact

Study Coordinator

clinicaltrials@anokion.com

651-300-2888

Columbus, Ohio

Status

Recruiting

Address

Aventiv Research, Inc. d/b/a Centricity Research

Columbus, Ohio, 43213

Site Contact

Study Coordinator

clinicaltrials@anokion.com

614-501-6164

The content provided by the Celiac Disease Foundation on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to: Privacy Policy and Terms of Use.